细胞遗传学风险对复发难治性急性髓系白血病异基因造血干细胞移植结局的影响
该研究基于EBMT注册数据,纳入2000-2017年间接受allo-HCT的2089例活动性疾病(复发或原发难治)AML患者,按MRC-UK细胞遗传学风险分层。中位随访49个月,中危和高危组较有利组无白血病生存和总生存更差、复发率更高;中危组中FLT3-ITD仍为不良预后因素;不同预处理强度间主要移植结局无差异。
要点
- 活动性疾病移植前细胞遗传学风险仍可区分预后组别。
- 中危和高危组无白血病生存和总生存更差、复发率更高。
- 中危组中FLT3-ITD突变仍与更差结局相关。
核心结论
- 在活动性疾病状态下接受allo-HCT的AML患者中,诊断时核型仍是重要预后因素,可据此将患者分为不同风险组。
- FLT3-ITD突变在该人群中仍是负性预后因素。
研究设计与样本
- 回顾性注册研究,基于EBMT急性白血病工作组数据,纳入2000-2017年间接受allo-HCT的2089例复发或原发难治AML患者。
- 细胞遗传学风险按MRC-UK标准分层:有利154例、中危1283例、高危652例;复发972例、原发难治1117例;中位随访49个月。
主要发现
- 与有利风险组相比,中危和高危患者无白血病生存和总生存更差,且复发发生率更高。
- 在中危风险组中,携带FLT3-ITD的患者结局更差,FLT3-ITD仍为重要预后因素。
- 按预处理方案强度分析,主要移植结局未见差异。
关键数值与推荐
- 细胞遗传学风险按MRC-UK标准分层。
- 有利风险154例,中危1283例,高危652例。
- 中位随访49个月。
临床怎么用
- 对活动性疾病(复发或原发难治)AML患者行allo-HCT前,应结合诊断时细胞遗传学风险进行预后分层。
- 中危组患者如携带FLT3-ITD,应视为负性预后因素加以考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Karyotypic analysis at time of diagnosis has an important value in determining initial response to treatment, remission duration and overall survival (OS) in acute myeloid leukemia (AML). Less is known about its value before allogeneic hematopoietic cell transplantation (allo-HCT) in patients transplanted with active disease, either relapsed or primary refractory (Rel-Ref) AML. We explored the impact of cytogenetic risk (stratification according to MRC-UK) in 2089 patients with either Ref (n = 972) or Rel AML (n = 1117) transplanted during the period 2000-2017. Overall, 154 patients had a favorable risk, 1283 had an intermediate risk and 652 had an adverse cytogenetic risk. Median follow-up was 49 months. Compared to the favorable risk group, intermediate and adverse risk patients were associated with worse leukemia-free survival and OS and also with a higher incidence of relapse. In a subgroup analysis of patients in the intermediate risk group harboring Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD), this remained an important prognostic factor, being associated with worse outcomes. When analyzing patients according to the intensity of the conditioning regimen, no differences were observed for the main transplant outcomes. In conclusion, in patients diagnosed with AML and transplanted with active disease, karyotype remains an important prognostic factor, allowing splitting patients into different risk groups according to their cytogenetics. Similarly, FLT3-ITD mutation also remains a negative prognostic factor in this population.
引用
- Poiani M, Labopin M, Battipaglia G, et al. The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT). Am J Hematol. 2020. PMID: 32944990. doi:10.1002/ajh.26000
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。